Dpb Antibiotics Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 1.00 M
- Company Age 14 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Profit Growth -0.60%
- Ebitda -44.81%
- Net Worth -1.48%
- Total Assets 3.24%
About Dpb Antibiotics
Dpb Antibiotics Private Limited (DAPL) is a Private Limited Indian Non-Government Company incorporated in India on 27 March 2010 and has a history of 14 years and ten months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Devang Ajmera, Piyush Ajmera, and Bhavin Ajmera serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51397MH2010PTC201353
-
Company No.
201353
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
27 Mar 2010
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Dpb Antibiotics?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Devang Ajmera
|
Director | 27-Mar-2010 | Current |
|
Piyush Ajmera
|
Director | 27-Mar-2010 | Current |
|
Bhavin Ajmera
|
Director | 27-Mar-2010 | Current |
Financial Performance of Dpb Antibiotics.
Dpb Antibiotics Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 0.6% decrease in profit. The company's net worth dipped by a decrease of 1.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dpb Antibiotics?
In 2023, Dpb Antibiotics had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Dpb Pharmaceuticals LimitedDevang Ajmera, Piyush Ajmera and 1 more are mutual person
-
Vardhman Chemtech LimitedDevang Ajmera, Piyush Ajmera and 1 more are mutual person
-
Kinvan Private LimitedDevang Ajmera is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dpb Antibiotics?
Unlock and access historical data on people associated with Dpb Antibiotics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dpb Antibiotics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dpb Antibiotics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.